2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
September 17th 2021
Frits van Rhee, MD, PhD, discusses the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.
September 3rd 2021
Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.
February 12th 2021
Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.